Susquehanna International Group
ADAP

Susquehanna International Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Susquehanna International Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,100
Closed -$22.4K – 11859
2024
Q2 		$22.4K Buy
23,100
+9,500
+70% +$10.4K ﹤0.01% 11640
2024
Q1 		$21.5K Buy
+13,600
New +$16.4K ﹤0.01% 11804
2022
Q3 		– Sell
-37,400
Closed -$64K – 13065
2022
Q2 		$64K Sell
37,400
-79,300
-68% -$136K ﹤0.01% 11823
2022
Q1 		$240K Buy
116,700
+34,600
+42% +$93.4K ﹤0.01% 10798
2021
Q4 		$308K Sell
82,100
-116,400
-59% -$530K ﹤0.01% 10439
2021
Q3 		$1.03M Buy
198,500
+107,000
+117% +$480K ﹤0.01% 7497
2021
Q2 		$390K Sell
91,500
-70,200
-43% -$341K ﹤0.01% 10195
2021
Q1 		$859K Buy
161,700
+28,400
+21% +$163K ﹤0.01% 8123
2020
Q4 		$718K Buy
133,300
+87,800
+193% +$477K ﹤0.01% 7476
2020
Q3 		$363K Sell
45,500
-164,400
-78% -$1.44M ﹤0.01% 8324
2020
Q2 		$2.1M Buy
+209,900
New +$1.32M ﹤0.01% 4401
2018
Q4 		– Sell
-82,700
Closed -$1.12M – 8836
2018
Q3 		$1.12M Buy
82,700
+29,600
+56% +$310K ﹤0.01% 5001
2018
Q2 		$630K Sell
53,100
-34,200
-39% -$426K ﹤0.01% 6345
2018
Q1 		$980K Buy
87,300
+71,200
+442% +$623K ﹤0.01% 5278
2017
Q4 		$108K Buy
+16,100
New +$124K ﹤0.01% 8658

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's ADAP Position: Q4 2025 in Review

Susquehanna International Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 308,065 shares — an estimated $40K sold.

Susquehanna International Group first reported a position in ADAP in Q4 2015 and held it in 22 quarters. The position peaked at $1.16M in Q3 2021. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Susquehanna International Group reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 308,065 Adaptimmune Therapeutics shares in Q4 2025, an estimated $40K.
  • Susquehanna International Group first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 22 quarters.
  • Susquehanna International Group's Adaptimmune Therapeutics position peaked at $1.16M in Q3 2021.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.